PLAU and cancer: Many studies have demonstrated that fisetin can inhibit cancer migration and invasion by suppressing the p38 MAPK-dependent NF-κB signaling pathway, causing downregulation of urokinase-type plasminogen activator (uPA) [44] and reducing cancer cell growth and proliferation by inducing apoptosis mediated by ER stress [45].